2,721 results on '"E. Reyes"'
Search Results
52. Speciation and Characterization of E-Waste, Using Analytical Techniques
53. Characterization of Waste Molding Sands, for Their Possible Use as Building Material
54. Genomic Evidence Suggests Viral Persistence of SARS-CoV-2 for 386 Days in Health Worker: A Case Report from Santiago of Chile
55. Synthesis and characterization of cesium lead bromide perovskite quantum dots with photovoltaic applications
56. Genetic diversity and relatedness inferred from microsatellite loci as a tool for broodstock management of fine flounder Paralichthys adspersus
57. Full-Space Potential Gradient Driven Charge Migration inside BiFeO3 Photocathode
58. Application of fractional calculus in the mechanical and dielectric correlation model of hybrid polymer films with different average molecular weight matrices
59. Comparative Study by Sol-Gel Acrylamide Polymerization via Microwave and Solid State Synthesis Methods in (Er2−x Srx)Ru2O6 System
60. Handy EKG: a low-cost 3-lead electrocardiograph for primary care
61. CRISPR Editing Takes Aim at Ischemia/Reperfusion Injury
62. Supplementary Figure 8 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
63. Supplementary Figure 6 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
64. Supplementary Figure 1 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
65. Supplementary Figure 7 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
66. Data from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
67. Supplementary Figure 5 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
68. Supplementary Figure 4 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
69. Supplementary Figure 2 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
70. Supplementary Figure 9 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
71. Supplementary Figure 3 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
72. Supplementary Table from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
73. Supplementary Figure 4 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
74. Supplementary Figure Legends from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
75. Supplementary Figure 1 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
76. Supplementary Figure 6 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
77. Supplementary Figure 3 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
78. Supplementary Figure 2 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
79. Data from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
80. Supplementary Figure 5 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
81. Supplementary Figure 6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
82. Supplementary Figure 2 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
83. Supplementary Figure 1 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
84. Supplementary Figure 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
85. Supplementary Figure Legends 1-6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
86. Supplementary Figure 3 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
87. Supplementary Tables 1 - 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
88. Supplementary Figure 5 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
89. Relationship between Leaf Degradation and Pore Water Chemistry in Two Mangrove Forests of Southeastern Mexico
90. A Mathematical Analysis of Masaccio's Trinity.
91. An efficiency comparison between a 18 pulses diode rectifier and a multi-cell AFE rectifier operating with FCS - MPC.
92. Caracterización y estudio preliminar de lixiviación de plata contenida en un concentrado de plomo
93. Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers
94. Analysis of truncated growth hormone receptor 1 in the differential growth of fine flounder Paralichthys adspersus
95. Validación experimental de un Observador de Alta Ganancia Reconfigurable para una columna de destilación
96. Canvas Model as a Tool for Research Projects: A Theoretical Approach
97. Genome-wide CRISPR screen reveals genetic modifiers of Ca2+-mediated cell death
98. Synthesis and Structural Characterization of Eu2TiO5 Using Atomic Substitution with Eu+3 in BaTiO3
99. Citrus mealybug insecticide trial 2, 2022
100. ÉTUDE NUMÉRIQUE DE LA COLLECTE DE PARTICULES D'AÉROSOL PAR DES GOUTTES EN CHUTE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.